Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3    exchanges : Nyse    save search
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.91% H: 0.35% C: -0.21%
EXEL | $22.47 -1.75% -1.78% 2.6M twitter stocktwits trandingview |
Health Technology
 | | O: 1.67% H: 0.0% C: -5.67%
osmic-313 kidney trial cancer phase 3 nivolumab
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
ADCT | $4.76 -4.03% 0.0% 280K twitter stocktwits trandingview |
Health Technology
 | | O: 0.19% H: 0.0% C: -8.91%
zynlonta biopharma trial china phase 3
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
Published: 2022-07-10 (Crawled : 16:20) - globenewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
haemophilia phase 3
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $42.16 -4.25% 0.85% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -0.11% H: 0.14% C: -0.17%
trial phase 3
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 1.85% H: 1.45% C: 0.66%
VERU | $1.42 22.41% 18.31% 7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.26% H: 20.43% C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Published: 2022-06-30 (Crawled : 01:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.51% H: 0.0% C: 0.0%
takhzyro children trial positive results phase 3
Alamos Gold Announces Phase 3+ Expansion of Island Gold to 2,400 tpd, Driving a Larger, More Profitable Operation with Average Annual Gold Production of 287k oz, Industry Low All-in Sustaining Costs of $576/oz, and a 31% Increase in Net Present Value (“NPV”) to $2.0 Billion at $1,850/oz Gold
Published: 2022-06-28 (Crawled : 23:00) - globenewswire.com
AGI | $15.06 0.8% -0.13% 1.5M twitter stocktwits trandingview |
Non-Energy Minerals
 | | O: 2.87% H: 2.65% C: 1.54%
expansion profitable phase 3
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Published: 2022-06-17 (Crawled : 11:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M twitter stocktwits trandingview |
Health Technology
 | | O: -0.74% H: 0.0% C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0 twitter stocktwits trandingview |
Health Technology
 | | O: 3.13% H: 8.66% C: 6.63%
sciences women lancet therapy publication phase 3
Bavarian Nordic Provides Update on the Phase 3 Program for its COVID-19 Booster Vaccine Candidate
Published: 2022-06-16 (Crawled : 10:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M twitter stocktwits trandingview |
Health Technology
 | | O: -0.77% H: 0.0% C: 0.0%
covid-19 vaccine program update phase 3
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray
Published: 2022-06-13 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $42.16 -4.25% 0.85% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -0.41% H: 0.44% C: 0.14%
nurtec migraine phase 3
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
Published: 2022-06-09 (Crawled : 13:00) - biospace.com/
BHVN | News 0 d | $42.16 -4.25% 0.85% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -0.08% H: 0.25% C: -0.26%
nurtec label trial migraine phase 3
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
Published: 2022-06-08 (Crawled : 12:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 3.02% H: 0.98% C: 0.34%
RIGL | $1.06 -4.51% -4.72% 1.2M twitter stocktwits trandingview |
Health Technology
 | | O: -45.22% H: 9.28% C: -21.07%
anemia trial results topline phase 3
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M twitter stocktwits trandingview |
Health Technology
 | | O: 1.03% H: 0.0% C: 0.0%
opdivo trial plus phase 3 nivolumab
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M twitter stocktwits trandingview |
Health Technology
 | | O: 1.03% H: 0.0% C: 0.0%
treatment opdivo trial plus cancer phase 3 nivolumab
Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Published: 2022-06-03 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K twitter stocktwits trandingview |
Communications
 | | O: -2.68% H: 0.0% C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M twitter stocktwits trandingview |
Health Technology
 | | O: -0.37% H: 0.0% C: 0.0%
imbruvica risk disease results order phase 3
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
Published: 2022-06-01 (Crawled : 15:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M twitter stocktwits trandingview |
Health Technology
 | | O: -0.55% H: 0.0% C: 0.0%
rinvoq trials positive results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M twitter stocktwits trandingview |
Health Technology
 | | O: -1.98% H: 0.0% C: 0.0%
skyrizi disease lancet risankizumab results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M twitter stocktwits trandingview |
Health Technology
 | | O: -1.98% H: 0.0% C: 0.0%
rinvoq lancet results phase 3 ulcerative colitis
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Published: 2022-05-24 (Crawled : 08:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 1.29% H: 1.3% C: 0.74%
year one phase 3 ulcerative colitis
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
Published: 2022-05-23 (Crawled : 16:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M twitter stocktwits trandingview |
Health Technology
 | | O: -0.51% H: 0.0% C: 0.0%
vraylar treatment positive phase 3 major depressive disorder
Gainers vs Losers
64% 36%

Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M twitter stocktwits trandingview |
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M twitter stocktwits trandingview |
Commercial Services
INVO | $1.555 104.6% 51.13% 5M twitter stocktwits trandingview |
Health Technology
ISPC | $0.437 105.16% 49.53% 37M twitter stocktwits trandingview |
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M twitter stocktwits trandingview |

OST | $0.499 21.38% 45.26% 1.9M twitter stocktwits trandingview |

XPON | News | $3.1 60.62% 37.74% 17M twitter stocktwits trandingview |

TIRX | $0.7 44.39% 30.74% 58M twitter stocktwits trandingview |

BNTC | News | $6.92 44.17% 30.64% 3.5M twitter stocktwits trandingview |
Health Technology
GGE | $0.035 19.86% 29.3% 64M twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.